BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 3783203)

  • 1. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
    Gelber RD; Goldhirsch A
    J Clin Oncol; 1986 Dec; 4(12):1772-9. PubMed ID: 3783203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
    Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
    Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
    Ludwig Breast Cancer Study Group
    Lancet; 1984 Jun; 1(8389):1256-60. PubMed ID: 6144974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
    Taylor SG; Knuiman MW; Sleeper LA; Olson JE; Tormey DC; Gilchrist KW; Falkson G; Rosenthal SN; Carbone PP; Cummings FJ
    J Clin Oncol; 1989 Jul; 7(7):879-89. PubMed ID: 2661734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
    Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
    J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.
    Gelber RD; Goldhirsch A; Cavalli F
    Ann Intern Med; 1991 Apr; 114(8):621-8. PubMed ID: 2003707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
    J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment in operable breast cancer.
    Goldhirsch A
    J Steroid Biochem; 1985 Dec; 23(6B):1155-60. PubMed ID: 3912622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Taylor SG; Gray R; Olson JE
    Recent Results Cancer Res; 1984; 96():110-6. PubMed ID: 6396764
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Martin JK; Votava HJ; Wold LE; Krook JE; Cullinan SA; Paulsen JK; Twito DI
    J Clin Oncol; 1988 Sep; 6(9):1388-96. PubMed ID: 3047333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.
    International Breast Cancer Study Group
    Ann Oncol; 1990; 1(1):30-5. PubMed ID: 2078483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
    Goldhirsch A; Gelber RD; Simes RJ; Glasziou P; Coates AS
    J Clin Oncol; 1989 Jan; 7(1):36-44. PubMed ID: 2642538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.